نتایج جستجو برای: warfarin therapy

تعداد نتایج: 660238  

Journal: :Postgraduate medical journal 1994
C G Suresh D Neal M O Coupe

A patient suffering from migraine, whose symptoms were abolished by warfarin therapy, is reported. Warfarin was prescribed for deep vein thrombosis and the frequency of the patient's headache improved remarkably during the anticoagulant therapy. Because of the unusual nature of the response to anticoagulant therapy, warfarin was reintroduced on a double blind (versus placebo) basis and once aga...

Journal: :Trials 2021

Abstract Background Endoscopic removal of colorectal adenoma is considered an effective treatment for reducing the mortality rates associated with cancer. Warfarin, a type anticoagulant, widely used and prevention thromboembolism; however, bleeding may increase its administration after polypectomy. In recent times, high incidence endoscopic polypectomy has been reported in patients receiving he...

2016
Teoh Chee Jia Aniza Abd Aziz Nadiah Wan-Arfah Nyi Nyi Naing

Article history: Received on: 01/06/2016 Revised on: 18/08/2016 Accepted on: 05/09/2016 Available online: 29/11/2016 This study was conducted to evaluate the changes in warfarin doses among patients after heart valve surgery and atrial fibrillation. A total of 137 patients having AF, AVR and MVR whom initiate warfarin therapy in year 2008 till 2010 in Penang Hospital were selected as samples fo...

Journal: :SpringerPlus 2016
Amr Mohamed Fahmi Osama Abdelsamad Hazem Elewa

INTRODUCTION Warfarin therapy is associated with many drug interactions that may cause a significant alteration in its anticoagulant effect. Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19. PRESENTATION We report a ...

Journal: :Circulation. Arrhythmia and electrophysiology 2014
Chung-Wah Siu Hung-Fat Tse

BACKGROUND Little is known about the net clinical benefit of warfarin therapy in elderly patients with atrial fibrillation. METHODS AND RESULTS We studied 2339 Chinese patients with nonvalvular atrial fibrillation aged≥80 years: 1805 with no antithrombotic therapy and 534 on warfarin therapy. Patients were stratified according to their CHA2DS2-VASc and HAS-BLED score. The primary end point wa...

Journal: :Pediatrics 2003
Fiona Newall Chris Barnes Helen Savoia Janine Campbell Paul Monagle

OBJECTIVE To determine whether warfarin can be safely administered to children who require long-term total parenteral nutrition (TPN), for the purpose of preventing central venous access device (CVAD)-related thrombosis. METHODS A prospective cohort study was conducted of 8 children with short-gut syndrome or small intestinal anomalies. All patients received oral anticoagulant therapy (warfar...

Journal: :Thrombosis research 2011
James D Douketis

Combination warfarin-ASA therapy is currently used in approximately 800,000 patients in North America as long-term treatment for the primary and secondary prevention of atherothrombotic and thromboembolic diseases. Despite a potentially complementary action of anticoagulant and antiplatelet drugs, the use of combination warfarin-ASA therapy is not based on compelling evidence of a net therapeut...

Journal: :Journal of the American Heart Association 2016
Kum Hyun Han W Charles O'Neill

BACKGROUND Matrix Gla protein is a vitamin K-dependent inhibitor of vascular calcification. Warfarin use is associated with increased breast arterial calcification, but whether this is reflective of other arteries or occurs in men is unclear. In this study, the prevalence of calcification in peripheral arteries was compared in patients with and without warfarin therapy. METHODS AND RESULTS Th...

Journal: :international journal of hematology-oncology and stem cell research 0
behzad poopak dcls,phd in hematology, islamic azad university, tehran medical sciences branch, tehran, iran saghar rabieipoor msc in biotechnology, payvand clinical and specialty laboratory, tehran, iran nazila safari msc in molecular oncology, payvand clinical and specialty laboratory, tehran, iran emadedin naraghi msc in bioscience, payvand clinical and specialty laboratory, tehran, iran fatemeh sheikhsofla msc in cell and molecular biology, payvand clinical and specialty laboratory, tehran, iran gelareh khosravipoor md, payvand clinical and specialty laboratory, tehran, iran 4msc in bioscience, payvand clinical and specialty laboratory, tehran, iran

background: although catalytic properties of different genetic polymorphisms of vkorc1 and cyp2c9 products have been identified, there is limited study available regarding warfarin dose requirement in iranian patient population. this study investigates the impact of these polymorphisms on 115 patients, referred to payvand clinical and specialty laboratory for determining the appropriate dose of...

2015
Dov Shiffman Marco V. Perez Lance A. Bare Judy Z. Louie Andre R. Arellano James J. Devlin

BACKGROUND Atrial fibrillation (AF) increases risk of stroke, and although this stroke risk can be ameliorated by warfarin therapy, some patients decline to adhere to warfarin therapy. A prospective clinical study could be conducted to determine whether knowledge of genetic risk for AF could increase adherence to warfarin therapy for patients who initially declined therapy. As a prelude to a po...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید